@misc{oai:repo.qst.go.jp:00071518,
 author = {Yuan, Qinghua and Furukawa, Takako and Jin, Zhao-Hui and U, Winn Aung and Yoshii, Yukie and Sugyou, Aya and Nagatsu, Kotaro and Endo, Hiroko and Inoue, Masahiro and Masuko, Takashi and Fujibayashi, Yasuhisa and Saga, Tsuneo and 元 清華 and 古川 高子 and 金 朝暉 and Ｕ Ｗｉｎｎ Ａｕｎｇ and 吉井 幸恵 and 須尭 綾 and 永津 弘太郎 and 藤林 康久 and 佐賀 恒夫},
 month = {Sep},
 note = {Cancer Tissue-Originated Spheroid (CTOS) is a recently developed tissue culture method, in which the properties of original tumors are preserved through maintaining the cell-cell contact (1). CTOS provides a unique model for cancer research and the characterization of CTOSs have revealed that HER3 signaling plays important role in the growth and remodeling of CTOSs, the process related to the malignant properties of cancer (unpublished data). Postulating HER3 as a target reflecting cancer malignancy, we explored the possibility of in vivo imaging of HER3 expression using anti-HER3 antibody. 
An anti-HER3 monoclonal antibody (Mab#58) was conjugated with desferrioxamine (DF) using p-isothiocyanatobenzyl-desferrioxamine and labeled with Zr-89 produced in our institute, following the previously reported protocol (2). The number of DF attached to one IgG molecule was 2.3 in average, and the immunoactivity was preserved through the conjugation, confirmed by cell binding assay. The radiochemical purity after the purification was over 90 %, and the specific radioactivity was 40-110 MBq/mg. Biodistribution study of the Zr-89-labeled antibody in mice bearing both HER3 overexpressing Her3/RH7777 and the parent RH7777 xenografts on the back showed that in most of the tissues examined, including RH7777 xenograft, radioactivity in the tissue (%D/g) decreased or unchanged from day1 to day6 after the injection of the labeled antibody, while that in Her3/RH7777 xenograft increased from day1 to day4, reaching 12.2 %D/g. The radioactivity in Her3/RH7777 xenograft was significantly higher than that in RH7777 xenograft through day1 to day6, indicating specific accumulation of the labeled antibody.  Her3/RH7777 xenograft was visualized by a small animal PET, with the accumulation apparently higher than that in RH7777 xenograft, from day1 to day6. The xenografts of colon and lung CTOSs were also clearly visualized by small animal PET.  
The successful imaging demonstrated the feasibility of PET imaging of HER3 expressing tumors by Zr-89 labeled anti-HER3 antibody, which could lead to imaging of a malignant characteristic of cancer., The World Molecular Imaging Congress 2014},
 title = {Zr-89 immuno-PET imaging targeting HER3 expression in mouse models},
 year = {2014}
}